gastric emptying glp-1 Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. receptor agonists and GLP-1 and glucose-dependent insulinotropic GLP-1 Receptor Agonists in Gastrointestinal

Copper peptides have been studied in cosmetic science, but evidence strength varies

Cells at PDL3 were used as the minimally expanded control

Take home points: Empagliflozin has a large study that shows a small but significant reduction in death and heart failure hospitalizations (NNT for primary outcome = 63 patients for ~3 years) compared to placebo in patients with diabetes and CV disease Empagliflozin can cause urinary and genital infections and ketoacidosis with near normal glucose Because of its mechanism (spilling glucose through the urine), it may develop a role in diabetes mellitus type 1 Refrences: American Diabetes Association: Standards of medical care in diabetes - 2016

Carcinogenesis 2007